| MDS/MPN-RS-T Justified Inclusion as a Unique Disease Entity? |
|
Best practice & research. Clinical haematology |
Myelodysplastic Syndromes (MDS), Myeloproliferative Neoplasms (MPN) |
| Establishing Specific Response Criteria for MDS/MPN - Getting Closer to Reality? |
|
Best practice & research. Clinical haematology |
Myelodysplastic Syndromes (MDS), Myeloproliferative Neoplasms (MPN) |
| Myelodysplastic/myeloproliferative Neoplasm, Unclassifiable (MDS/MPN-U): More Than Just a "Catch-All" Term? |
|
Best practice & research. Clinical haematology |
Myelodysplastic Syndromes (MDS), Myeloproliferative Neoplasms (MPN) |
| Randomized trials with checkpoint inhibitors in acute myeloid leukaemia and myelodysplastic syndromes: What have we learned so far and where are we heading? |
|
Best practice & research. Clinical haematology |
Myelodysplastic Syndromes (MDS) |
| Establishing Specific Response Criteria for MDS/MPN - Getting Closer to Reality? |
|
Best practice & research. Clinical haematology |
Myelodysplastic Syndromes (MDS) |
| Standardization of Bone Marrow Reporting for Myelodysplastic Syndromes/Neoplasms on Behalf of the International Consortium for Myelodysplastic Syndromes/Neoplasms |
|
Archives of Pathology & Laboratory Medicine |
Myelodysplastic Syndromes (MDS) |
| Clonal Hematopoiesis, Inflammation, and Hematologic Malignancy |
|
Annual Review of Pathology: Mechanisms of Disease |
Aplastic Anemia, Myelodysplastic Syndromes (MDS), Paroxysmal Nocturnal Hemoglobinuria (PNH) |
| A Journey from Blood Cells to Genes and Back |
|
Annual Review of Genomics and Human Genetics |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
| Myelodysplastic syndromes: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up |
|
Annals of Oncology: Official Journal of the European Society for Medical Oncology |
Myelodysplastic Syndromes (MDS) |
| Iron Chelation in Transfusion-Dependent Patients With Low- to Intermediate-1-Risk Myelodysplastic Syndromes |
|
Annals of internal medicine |
Myelodysplastic Syndromes (MDS) |
